z-logo
open-access-imgOpen Access
Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity
Author(s) -
Hugh A. Sampson,
Wayne G. Shreffler,
William H. Yang,
Gordon L. Sussman,
Terri F. BrownWhitehorn,
Kari C. Nadeau,
Amarjit Cheema,
Stephanie A. Leonard,
Jacqueline A. Pongracic,
Christine Sauvage-Delebarre,
Amal Assa’ad,
F. de Blay,
J. Andrew Bird,
Stephen A. Tilles,
F. Boralévi,
T. Bourrier,
Jacques Hébert,
Todd D. Green,
Roy Gerth van Wijk,
André C. Knulst,
Gisèle Kanny,
Lynda C. Schneider,
Marek L. Kowalski,
Christophe Dupont
Publication year - 2017
Publication title -
jama
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.688
H-Index - 680
eISSN - 1538-3598
pISSN - 0098-7484
DOI - 10.1001/jama.2017.16591
Subject(s) - medicine , placebo , adverse effect , peanut allergy , quartile , clinical endpoint , clinical trial , allergy , randomized controlled trial , food allergy , gastroenterology , surgery , immunology , confidence interval , alternative medicine , pathology
Epicutaneous immunotherapy may have potential for treating peanut allergy but has been assessed only in preclinical and early human trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom